R&D channel feed

#AACR: Mer­ck spot­lights piv­otal Keytru­da/chemo da­ta, hop­ing to break down skep­ti­cism to its front­line lung can­cer duo

8 years ago

#AACR: Bris­tol-My­ers tunes out sta­t­ic, broad­casts im­pres­sive re­sults for Op­di­vo/Yer­voy lung can­cer com­bo

8 years ago

#AACR18 round 1: Mer­ck takes a di­rect swing at Bris­tol-My­ers with ad­ju­vant melanoma da­ta for Keytru­da

8 years ago

Al­ny­lam flags loom­ing FDA ap­pli­ca­tion for givosir­an, adding an­oth­er round of stel­lar ef­fi­ca­cy da­ta from ear­ly study

8 years ago

Af­ter pa­tient deaths, failed part­ner­ships and a stock scan­dal, Han­mi fi­nal­ly gives up on con­tro­ver­sial ol­mu­tinib. What did we learn?

8 years ago

Penn team spot­lights a pi­lot ovar­i­an can­cer tri­al and sur­vival rates for a per­son­al­ized can­cer vac­cine

8 years ago
Discovery

Con­tin­u­ing an R&D re­vamp, Glax­o­SmithK­line hands off its rare dis­ease unit to Or­chard Ther­a­peu­tics

8 years ago

Bel­licum shares surge as FDA lifts a clin­i­cal hold on lead cell ther­a­py fol­low­ing a pro­to­col ad­just­ment

8 years ago

Roche halts en­roll­ment in a PhII com­bo study of Tecen­triq and Cotel­lic in wake of sev­er­al pa­tient deaths

8 years ago

Pfiz­er’s PhI­II kid­ney can­cer study for In­ly­ta flops as in­ves­ti­ga­tors flag a dead end on out­comes

8 years ago

Af­ter yet an­oth­er PhI­II Alzheimer's fail­ure, ex­perts try to map a path out of the wreck­ing field

8 years ago

The drum­beat of Alzheimer’s PhI­II fail­ures con­tin­ues as vTv drug is out­per­formed by a place­bo, shares crash

8 years ago

Ab­b­Vie’s promised rheuma­toid arthri­tis block­buster upadac­i­tinib hits its marks in an­oth­er PhI­II — this time with­out any deaths

8 years ago

Ther­a­pix shares rise on ear­ly da­ta of its re­pur­posed cannabi­noid in Tourette syn­drome

8 years ago

Mer­ck racks up an­oth­er win in wide-rang­ing PhI­II Keytru­da lung can­cer study, this time as so­lo ther­a­py

8 years ago

Men­lo’s IPO hang­over be­gins with a failed PhII for an old Mer­ck castoff

8 years ago

Keytru­da/epaca­do­stat com­bo crash­es in PhI­II melanoma study, rais­ing ques­tions about the fu­ture of IDO for In­cyte

8 years ago

Evo­lus touts equal ef­fi­ca­cy for its Botox me-too drug in PhI­II Eu­ro­pean/Cana­di­an tri­als

8 years ago

No­var­tis-backed Cona­tus high­lights a sil­ver lin­ing, but PhI­Ib NASH-re­lat­ed set­back caus­es whiplash in share price

8 years ago

Boehringer In­gel­heim is think­ing in block­buster terms as it throws its hat in­to the ever-widen­ing CD47 ring

8 years ago
Pharma

Eli Lil­ly jumps in­to a $473M hunt with Sig­ilon for the Holy Grail in di­a­betes cell ther­a­pies

8 years ago
Pharma

A gene ther­a­py mys­tery? Gen­Sight blast­ed as 1st PhI­II eye study ends in an in­trigu­ing fail­ure

8 years ago
Cell/Gene Tx

Al­ler­gan, Richter prep for FDA OK with pos­i­tive PhI­II for cariprazine in bipo­lar de­pres­sion

8 years ago

Rigel hit with an­oth­er tri­al set­back as lead drug fos­ta­ma­tinib fails PhII

8 years ago
First page Previous page 275276277278279280281 Next page Last page
A service from the Financial Times